Share your videos with the world

Sign Up | Log In | Help  

   
 
Related Tags: cancer  treatment  medical  medicine  fda  ctca  educational  awareness  multivu  8295651  health  medical  device  3d  fda  gore  procedure  stroke  heart  multivu  8301551  health  heart  abbott  fda  valve  doctors  healthcare  children  multivu  8280551  auto  car  price  fixing  settlement  payout  money  legal  lawsuit  repairs  multivu  7982351  ketel  one  vodka  alcohol  perfect  ad  commercial  identity  theft  signature  multivu  7975151  hearing  fda  loss  hearing  aid  cochlear  limited  kanso  style  discrete  multivu  7658352  food  drug  administration  fda  abbott  tecnis  symfony  sight  eyes  treatment  cataracts  multivu  7870151  abbott  health  heart  procedure  fda  coronary  artery  disease  food  drug  administration  multivu  7826651  aspiresr  vns  therapy  fda  approval  epilepsy  drug  resistant  health  seizures  medication  doctor  multivu  7651751  fda  approval  boston  scientific  coronary  artery  disease  drug  research  science  health  multivu  7223456  abbott  idesign  nasa  lasik  hubble  telescope  james  webb  space  eye  vision  multivu  7571951  ytica  limited  pericoach  women  pelvic  bladder  health  kegel  muscle  exercise  training  medical  device  multivu  7543451 
Search // approval
Results 1-12 of 32 for ' approval ' (5 seconds)
Cancer Treatment Centers of America® (CTCA), a national network of comprehensive cancer care hospitals and outpatient care centers, and Foundation Medicine, a leading molecular insights company that recently received FDA approval for its FoundationOne CDx™ genomic test, today announced the launch of a collaborative educational campaign designed to heighten awareness of the promise of precision medicine and the role that advanced genomic testing plays in helping identify treatments best suited for individual patients. To view the multimedia release go to: https://www.multivu.com/players/English/8295651-cancer-treatment-centers-of-america-foundation-medicine-precision-cancer-treatment/
Categories // Miscellaneous 
Added: 103 days ago by MultiVuVideos
Runtime: 0m27s | Views: 4 | Comments: 3
Not yet rated
 

 

 

Following the unprecedented Gore REDUCE Clinical Study conclusion that closure of patent foramen ovale (PFO) can prevent recurrent ischemic strokes, W. L. Gore & Associates, Inc. (Gore) has received approval from the U.S. Food and Drug Administration (FDA) for an expanded indication for its GORE® CARDIOFORM Septal Occluder. The device, already approved for closure of atrial septal defects (ASDs) up to 17 mm, is now also approved for the closure of PFO to reduce the risk of recurrent ischemic stroke in certain patients.* To view the multimedia release go to: https://www.multivu.com/players/English/8301551-gore-cardioform-septal-occluder-fda-approval/
Categories // Miscellaneous 
Added: 108 days ago by MultiVuVideos
Runtime: 1m8s | Views: 4 | Comments: 4
Not yet rated
 

 

 

Abbott today announced the U.S. Food and Drug Administration (FDA) approved the Masters HP™ 15mm rotatable mechanical heart valve, the world’s smallest mechanical heart valve, that will allow doctors to treat babies and toddlers in need of a mitral or aortic valve replacement. Until today, surgeons could only use a range of larger-sized valves to replace a pediatric heart valve that could not be repaired, and larger valves are often not suitable given the smaller size of children’s hearts. This dime-sized new valve is the first and only pediatric mechanical heart valve developed for newborns and infants, and offers hope for pediatric patients in urgent need of treatment who have no other approved options. To view the multimedia release go to: https://www.multivu.com/players/English/8280551-abbott-pediatric-heart-valve-fda-approval/
Categories // Miscellaneous 
Added: 136 days ago by MultiVuVideos
Runtime: 0m47s | Views: 4 | Comments: 3
Not yet rated
 

 

 

The following is being released by the Notice Provider, Kinsella Media, LLC, about the lawsuit In re Automotive Parts Antitrust Litigation, MDL No. 2311. There is an update for affected purchasers in this lawsuit about certain vehicle components, as there have been additional Settlements that may affect their rights. Twelve additional Defendants have agreed to Settlements resolving claims that they fixed the price of certain vehicle components. (The Court previously approved settlements with 11 Defendants, totaling approximately $225 million.) The additional Settlements being presented for Court Approval total approximately $379 million. The lawsuits allege that Defendants fixed the price of certain vehicle components, causing millions of consumers and businesses from around the country to pay more for certain new or leased vehicles and replacement parts. A complete list of included parts is available at the website, www.AutoPartsClass.com. To view the multimedia release go to: http://www.multivu.com/players/English/7982351-auto-parts-class-action-settlements/
Categories // Miscellaneous 
Added: 599 days ago by MultiVuVideos
Runtime: 0m30s | Views: 66 | Comments: 0
Not yet rated
 

 

 

At the heart of Ketel One Vodka lies one family’s unwavering passion for crafting the world’s finest spirits. Inspired by over 325 years of distilling expertise, the Nolet family brings old-world pot still craft and modern distilling techniques together in one flawless process. From Joannes to Jacobus to Carolus Sr., creator of Ketel One Vodka, to Carolus Jr. and Bob Nolet today, each of the 11 generations of Nolet family distillers is tasked with upholding a legacy of distilling excellence. Some may consider the Nolets a little obsessive, but those individuals just don’t understand. Everything must be done with meticulous attention to detail, because the family name is riding on every bottle of Ketel One Vodka. “We take our work very seriously, not ourselves,” said Carl Nolet Jr., 11th Generation Nolet Family Distillery. “The stories we tell are all true and based on family events, beliefs and the pressure of upholding 11 generations of legacy for generations to come.” To view the multimedia release go to: http://www.multivu.com/players/English/7975151-ketel-one-vodka
Categories // Miscellaneous 
Added: 599 days ago by MultiVuVideos
Runtime: 0m30s | Views: 54 | Comments: 0
Not yet rated
 

 

 

Cochlear Limited (ASX: COH), the global leader in implantable hearing solutions, announces today it has received U.S. Food and Drug Administration (FDA) approval for its newest innovative hearing loss solution, Kanso. The Kanso Sound Processor provides a distinct new way for cochlear implant users to hear. Unlike most hearing aids and current cochlear implant sound processors that are worn on the ear, Kanso is a small, off-the-ear hearing device that provides a more discreet hearing solution and delivers the same hearing experience as a behind-the-ear sound processor. The name Kanso is a Japanese word for ‘simplicity,’ and it was selected in recognition of Kanso’s all-in-one design. The Kanso Sound Processor features a single on/off button with no cables so it is easy to use. It is worn on the user’s head with nothing behind the ear, adding greater comfort for those with glasses, and it can be easily hidden under or blended within a user’s hair. To view the multimedia release go to: http://www.multivu.com/players/English/7658352-cochlear-kanso-fda-approval/
Categories // Miscellaneous 
Added: 683 days ago by MultiVuVideos
Runtime: 1m51s | Views: 102 | Comments: 0
Not yet rated
 

 

 

Abbott announced today that the U.S. Food and Drug Administration (FDA) has approved the Tecnis Symfony® Intraocular Lenses for the treatment of cataracts. The first in a new category of intraocular lenses (IOLs), the Tecnis Symfony lenses are the only lenses in the United States that provide a full range of continuous high-quality vision following cataract surgery, while also mitigating the effects of presbyopia by helping people focus on near objects. The FDA approval includes a version of the lens for people with astigmatism, the Tecnis Symfony Toric IOL. Cataracts are a common condition, with almost 4 million cataract surgeries performed each year, and that number is expected to increase.1 By age 80, more than half of all Americans either have a cataract or have had cataract surgery.2 However, cataracts do not just impact seniors. In 2016 it is estimated that nearly one in four cataract surgeries will be performed on people younger than 65.1 Many people who have cataracts experience other problems with their vision, such as presbyopia and astigmatism, which the Symfony lenses also address. Presbyopia, which affects most people over age 40, means people have lost the ability to focus on objects up close and often require glasses to perform near visual tasks. Astigmatism is when the cornea is misshapen, which causes blurry or distorted vision. To view the multimedia release go to: http://www.multivu.com/players/English/7870151-abbott-intraocular-lenses/
Categories // Miscellaneous 
Added: 736 days ago by MultiVuVideos
Runtime: 0m35s | Views: 117 | Comments: 0
Not yet rated
 

 

 

Abbott announced today that the U.S. Food and Drug Administration has approved the company’s Absorb bioresorbable heart stent, making the first-of-its-kind medical device commercially available to treat people with coronary artery disease in the United States. Absorb is the only fully dissolving stent approved for the treatment of coronary artery disease, which affects 15 million people in the United States and remains a leading cause of death worldwide, despite decades of therapeutic advances. While stents are traditionally made of metal, Abbott’s Absorb stent is made of a naturally dissolving material, similar to dissolving sutures. Absorb disappears completely in approximately three years, after it has done its job of keeping a clogged artery open and promoting healing of the treated artery segment. By contrast, metal stents are permanent implants that restrict vessel motion for the life of the person treated. To view the multimedia release go to: http://www.multivu.com/players/English/7826651-abbott-fda-approval-stent/
Categories // Miscellaneous 
Added: 744 days ago by MultiVuVideos
Runtime: 1m33s | Views: 139 | Comments: 0
Not yet rated
 

 

 

Following FDA approval of the AspireSR® generator for the VNS Therapy® system in June 2015, more than a thousand patients with drug-resistant epilepsy across the United States have received this new treatment option. Many of these patients are experiencing benefits which have positively impacted their lives – and are sharing their stories during Epilepsy Awareness Month with the hope of encouraging others to seek new treatments for drug-resistant epilepsy. Numerous hospitals nationwide have begun providing the AspireSR device to patients with drug-resistant epilepsy – a condition that affects as many as one-third of people with epilepsy, causing them to have seizures in spite of treatment with antiepileptic medications. The VNS Therapy system is a minimally invasive option in which a medical device is placed under the skin in the upper chest area during an outpatient procedure. The device sends mild electrical pulses through the vagus nerve to areas of the brain known to be associated with seizures. The new AspireSR generator takes the VNS Therapy technology a step further – detecting relative heart-rate increases that are often associated with seizures in people with epilepsy and providing responsive stimulation in an attempt to stop and shorten seizures and improve recovery. To view the multimedia release go to: http://www.multivu.com/players/English/7651751-livanova-aspiresr-treatment/
Categories // Miscellaneous 
Added: 981 days ago by MultiVuVideos
Runtime: 5m25s | Views: 192 | Comments: 0
    
 

 

 

Boston Scientific (NYSE: BSX) has received U.S. Food and Drug Administration (FDA) approval for the SYNERGY™ Bioabsorbable Polymer Drug-Eluting Stent System (BP-DES) for the treatment of coronary artery disease. With this FDA approval, Boston Scientific will commence commercialization of the first and only BP-DES in the U.S. Notably, both the drug coating and the polymer – which modulates drug release – are fully absorbed shortly after drug elution is complete at three months. The SYNERGY Stent provides synchronized drug and polymer absorption. It is designed to enable more rapid and complete arterial healing, and to thereby reduce the risk of complications associated with long-term polymer exposure compared to currently-used drug-eluting stents (DES) with permanent polymers. To view the multimedia release go to: http://www.multivu.com/players/English/7223456-boston-scientific-fda-approval-synergy/
Categories // Science and Technology 
Added: 1020 days ago by MultiVuVideos
Runtime: 0m45s | Views: 179 | Comments: 2
Not yet rated
 

 

 

Abbott announced today the U.S. Food and Drug Administration approval and launch of the iDesign Advanced WaveScan Studio System. The system acts as the "brain" of the LASIK procedure, generating a high-definition scan that measures and maps irregularities of the eye that may impact vision. From these measurements, the iDesign System creates an accurate and personalized LASIK treatment plan based on the unique "blueprint" of each person’s eyes. The iDesign System captures more than 1,200 micro readings of the eye, as well as identifying the shape of the cornea, its curvature, how light passes through the eye and pupil diameter under different lighting conditions – all in one, three-second scan that can be used to precisely correct vision. The development of the sensor technology within the iDesign System was the result of an earlier discovery by Abbott scientists, which NASA used to accurately measure and shape the mirrors in the James Webb Space Telescope to ensure it will transmit high resolution images of deep space back to earth. The telescope is scheduled to launch in 2018. To view the Multimedia News Release, please go to http://www.multivu.com/players/English/7571951-abbott-idesign-system-3-d-eye-map/
Categories // Science and Technology 
Added: 1097 days ago by MultiVuVideos
Runtime: 2m25s | Views: 261 | Comments: 2
Not yet rated
 

 

 

The millions of women who experience bladder leakage now have a new option to strengthen and tone away their problem instead of covering it up with pads. The PeriCoach System is a discreet device and smartphone app that helps women perform at-home pelvic floor muscle training, exercises recommended by the American College of Physicians as first-line treatment for urinary incontinence. PeriCoach is the only system that includes a web portal allowing clinicians to remotely monitor their patients’ progress. To view the Multimedia News Release, go http://www.multivu.com/players/English/7543451-pericoach-fda-approval/
Categories // People and Blog 
Added: 1123 days ago by MultiVuVideos
Runtime: 1m11s | Views: 204 | Comments: 1
Not yet rated
 

 

 

Page 1 of 3  |  Go to page    Next» LAST»»



About Us   |   Help  |   Advertise on ClipMoon   |   Terms of Use   |   Privacy Policy   |   Copyright   |   Contact   |   Link us   |   RSS 
Copyright © 2007-2018 ClipMoon.com. All rights reserved.